Takeuchi M, Katayama T, Inukai M
Fermentation Research laboratories, Sankyo Co., Ltd., Tokyo, Japan.
J Antibiot (Tokyo). 1991 Mar;44(3):278-81. doi: 10.7164/antibiotics.44.278.
Helvecardins (HVCs) A and B were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), but they were inactive against Gram-negative bacteria and fungi. Though HVC A showed only slightly stronger antimicrobial activity than beta-avoparcin (AVP), its in vivo protective activity against S. aureus infection in mice was greatly superior to AVP.
Helvecardins（HVCs）A和B对包括耐甲氧西林金黄色葡萄球菌（MRSA）在内的需氧和厌氧革兰氏阳性菌具有很强的活性，但对革兰氏阴性菌和真菌无活性。尽管HVC A的抗菌活性仅比β-阿伏帕星（AVP）略强，但其对小鼠金黄色葡萄球菌感染的体内保护活性却大大优于AVP。
